Refractory thyroid cancer: A paradigm shift in treatment is not far off

Journal of Clinical Oncology

Volumn 26, Issue 29, 2008, Pages 4701-4704

  Pfister, David G ^a   Fagin, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL; SOMATOSTATIN DERIVATIVE; SORAFENIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; EDITORIAL; GENE MUTATION; HUMAN; MELANOMA; PRIORITY JOURNAL; THYROID CANCER; UNSPECIFIED SIDE EFFECT;

HUMANS; THYROID NEOPLASMS;

EID: 50649101341     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.3682     Document Type: Editorial

References (40)

1. Cohen EEW, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol doi:10.1200/JCO.2007.15.9566 [epub ahead of print on June 9, 2008]
2. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol doi:10.1200/JCO.2008.16.3279 [epub ahead of print on June 9, 2008]
3. Cooper DS, Doherty GM, Haugen BR, et al: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142, 2006
4. Brenner H: Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 360:1131-1135, 2002
5. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428, 1994
6. Haugen BR: Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34-41, 1999
7. Shimaoka K, Schoenfeld D, DeWys WD, et al: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160, 1985
8. De Besi P, Busnardo B, Toso S, et al: Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14:475-480, 1991
9. Koong SS, Reynolds JC, Movius EG, et al: Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 84:912-916, 1999
10. Short SC, Suovuori A, Cook G, et al: A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol) 16:569-574, 2004
11. Robbins RJ, Hill RH, Wang W, et al: Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10:177-183, 2000
12. Kohlfuerst S, Igerc I, Gallowitsch HJ, et al: Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases? Thyroid 16:1113-1119, 2006
13. Pittas AG, Adler M, Fazzari M, et al: Bone metastases from thyroid carcinoma: Clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 10:261-268, 2000
14. Wang W, Larson SM, Fazzari M, et al: Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107-1113, 2000
15. Lim S, Lee NY, Fury MG, et al: Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: We need to do better. J Clin Oncol 25:669s, 2007 (abstr 16506)
16. Cupisti K, Wolf A, Raffel A, et al: Long-term biochemical and clinical follow-up in medullary thyroid carcinoma: A single institution's experience over 20 years. Ann Surg 246:815-821, 2007
17. Kimura ET, Nikiforova MN, Zhu Z, et al: High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457, 2003
18. Soares P, Trovisco V, Rocha AS, et al: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580, 2003
19. Xing M, Westra WH, Tufano RP, et al: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379, 2005
20. Ouyang B, Knauf JA, Smith EP, et al: Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12:1785-1793, 2006
21. Salvatore G, De FV, Salerno P, et al: BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12:1623-1629, 2006
22. Fenton C, Patel A, Dinauer C, et al: The expression of vascular endothelial growth factor and the type I vascular endothelial growth factor receptor correlates with the size of papillary thyroid cancer in children and young adults. Thyroid 10:349-357, 2000
23. Lennard CM, Patel A, Wilson J, et al: Intensity of vacular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129:552-558, 2001
24. Bauer AJ, Patel A, Terrell R, et al: Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. Ann Clin Lab Sci 33:192-199, 2003
25. Sherman SI, Schlumberger MJ, Droz J, et al: Initial results from a phase II trial of motesanib diphosphate (Amgen 706) in patients with differentiated thyroid cancer (DTC). J Clin Oncol 25:303s, 2007 (abstr 6017)
26. Wells SA, Gosnell JE, Gagel RF, et al: Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial. J Clin Oncol 25:303s, 2007 (abstr 6018)
27. Pennell NA, Daniels GH, Haddad RI, et al: A phase II study of gefitinib in patients with advanced thyroid cancer. J Clin Oncol 25:304s, 2007 (abstr 6020)
28. Schlumberger M, Elisei R, Sherman SI, et al: Phase 2 trial of motesanib diphosphate (AMG 706) in patients with medullary thyroid cancer (MTC). Presented at 89th Annual Meeting of the Endocrine Society, Toronto, Ontario, Canada; June 2-5, 2007
29. Robbins RJ, Wan Q, Grewal RK, et al: Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505, 2006
30. Rini BI, Tamaskar I, Shaheen P, et al: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83, 2007
31. de Groot JW, Zonnenberg BA, Plukker JT, et al: Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78:433-438, 2005
32. Sharma A, Trivedi NR, Zimmerman MA, et al: Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65:2412-2421, 2005
33. Eisen T, Ahmad T, Flaherty KT, et al: Sorafenib in advanced melanoma: A phase II randomized discontinuation trial analysis. Br J Cancer 95:581-586, 2006
34. Flaherty KT: Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 12:2366s-2370s, 2006
35. Chiloeches A, Marais R: Is BRAF the Achilles' Heel of thyroid cancer? Clin Cancer Res 12:1661-1664, 2006
36. Solit DB, Garraway LA, Pratilas CA, et al: BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362, 2006
37. Leboeuf R, Baumgartner JE, Benezra M, et al: BRAFV600E mutation is associated with preferential sensitivity to MEK inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab [epub ahead of print on April 1, 2008]
38. Ball DW, Jin N, Rosen DM, et al: Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 92:4712-4718, 2007
39. Liu D, Liu Z, Jiang D, et al: Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 92:4686-4695, 2007
40. National Comprehensive Cancer Network: NCCN Practice Guidelines in Oncology, version 2.2007: Thyroid Cancer. www.nccn.org